Main Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Opioid DependenceMethadone Withdrawal Syndrome
Interventions
DRUG

Lofexidine HCl

Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID \[e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 (3 tablets)QID, etc\] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.

DRUG

Lofexidine-matching sugar pill

Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc)as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.

Trial Locations (1)

84106

Lifetree Clinical Research, Salt Lake City

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

USWM, LLC (dba US WorldMeds)

INDUSTRY

NCT01650649 - Main Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients | Biotech Hunter | Biotech Hunter